对BRCA野生型三阴性乳腺癌的双PARP/NAMPT抑制剂:破坏同源重组修复和激活抗瘤免疫力
Kaizhen Wang1, Dexiang Wang1, Jun Tong1
1Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
Journal of medicinal chemistry
|January 17, 2026
概括
这项研究引入了化合物10n,一种新型的多 (ADP-ribose) 聚合酶 (PARP) 和NAMPT的双重抑制剂,通过诱导癌细胞死亡和增强免疫反应,显示出治疗BRCA野生型三阴性乳腺癌 (TNBC) 的重大前景.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 同时抑制PARP和NAMPT通过合成致死性在BRCA野生型三阴性乳腺癌 (TNBC) 中提供了协同效果.
- 这一策略扩大了PARP抑制剂的临床应用.
研究的目的:
- 合理设计和优化新型双 PARP / NAMPT 抑制剂.
- 在BRCA野生型TNBC模型中评估化合物 (10n) 的疗效和作用机制.
主要方法:
- 双 PARP / NAMPT 抑制剂的设计和合成.
- 在体外测试以确定抑制度 (IC50) 和细胞增殖抑制.
- 使用异种移植和转移性癌症模型的体内研究.
- 对DNA损伤,细胞亡,免疫细胞死亡 (ICD) 和cGAS-STING通路激活的分析.
主要成果:
- 化合物10n证明了对PARP1和NAMPT的强烈双重抑制 (IC50=1.2和6.7nM).
- 10n有效抑制了BRCA野生型TNBC细胞增殖,破坏了DNA修复,诱导了双链断裂,并促进了细胞亡.
- 在体内,10n·HCl在异种移植模型中显示出显著的抗瘤活性,并减少了肺转移.
- 10n·HCl诱导免疫细胞死亡并激活cGAS-STING通路,增强抗瘤免疫力.
结论:
- 化合物10n是开发双 PARP / NAMPT 抑制剂的有希望的主要候选者.
- 这种方法具有治疗BRCA野生型TNBC和刺激抗瘤免疫反应的潜力.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Long-patch Base Excision Repair
7.9K
Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are:
7.9K


